Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation

December 19, 2023

https://www.globenewswire.com/news-release/2023/12/19/2798537/0/en/Cellectar-Biosciences-Expands-Iopofosine-I-131-Collaboration-with-Wisconsin-Alumni-Research-Foundation.html

FLORHAM PARK, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin-Madison (UW) with iopofosine I 131 in pediatric cancers.

Read more at globenewswire.com

Related news for (CLRB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.